{"id":"oral-olanzapine","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Weight gain"},{"rate":"20-30","effect":"Sedation/somnolence"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Hyperglycemia/diabetes"},{"rate":"10-15","effect":"Hyperlipidemia"},{"rate":"5-10","effect":"Akathisia"},{"rate":"5-10","effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors and has activity at multiple other receptors (muscarinic, histamine H1, alpha-adrenergic), which contribute to its mood-stabilizing and anxiolytic effects. This multi-receptor profile distinguishes it from first-generation antipsychotics and provides efficacy across a broader range of psychiatric conditions.","oneSentence":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:50.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Agitation associated with schizophrenia or bipolar disorder"},{"name":"Adjunctive treatment of major depressive disorder"}]},"trialDetails":[{"nctId":"NCT07482891","phase":"PHASE4","title":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2026-03-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":200},{"nctId":"NCT07208305","phase":"PHASE3","title":"Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting","status":"RECRUITING","sponsor":"Affiliated Hospital of Qinghai University","startDate":"2026-02-03","conditions":"Nausea, Vomiting","enrollment":222},{"nctId":"NCT07442890","phase":"NA","title":"A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04-30","conditions":"Lung Cancer","enrollment":238},{"nctId":"NCT07413809","phase":"PHASE3","title":"Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2025-10-31","conditions":"Multiple Myeloma","enrollment":92},{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT05705492","phase":"PHASE2","title":"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-07-17","conditions":"Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma","enrollment":66},{"nctId":"NCT06315283","phase":"PHASE1","title":"An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2024-03-20","conditions":"Schizophrenia","enrollment":153},{"nctId":"NCT05676294","phase":"PHASE2","title":"The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery","status":"COMPLETED","sponsor":"Yale University","startDate":"2023-06-26","conditions":"Postoperative Nausea and Vomiting","enrollment":384},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT05964647","phase":"PHASE1","title":"Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-02-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT05590923","phase":"PHASE4","title":"Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting","status":"TERMINATED","sponsor":"The Guthrie Clinic","startDate":"2022-12-07","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":24},{"nctId":"NCT03118986","phase":"PHASE2","title":"RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy","status":"RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2017-08-10","conditions":"Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer","enrollment":200},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT07190482","phase":"PHASE1","title":"Treatment of Tinnitus With Olanzapine","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2023-10-01","conditions":"Tinnitus, Tinnitus, Subjective","enrollment":50},{"nctId":"NCT06175273","phase":"PHASE2, PHASE3","title":"Pediatric Oncology Nutrition Intervention Trial","status":"COMPLETED","sponsor":"Corey Hawes","startDate":"2024-01-31","conditions":"Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer","enrollment":19},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT06253546","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-03-28","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT07035821","phase":"PHASE3","title":"Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2025-07-01","conditions":"Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer","enrollment":100},{"nctId":"NCT04503668","phase":"PHASE3","title":"Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-12-28","conditions":"Gynecologic Cancer","enrollment":62},{"nctId":"NCT05805800","phase":"PHASE3","title":"Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV","status":"COMPLETED","sponsor":"Xingchen Peng","startDate":"2023-04-15","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":275},{"nctId":"NCT03781115","phase":"PHASE1","title":"Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2017-11-20","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03629951","phase":"","title":"A Study for Schizophrenia Relapse Prediction","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-29","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT00394095","phase":"PHASE4","title":"Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2006-12","conditions":"Bipolar Disorder, Weight Gain","enrollment":31},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT05635227","phase":"NA","title":"Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-11-10","conditions":"Coronary Artery Disease, Aortic Valve Disease","enrollment":1200},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT06107803","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Minerva Neurosciences","startDate":"2023-10-13","conditions":"Negative Symptoms in Schizophrenia","enrollment":17},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT06850454","phase":"PHASE3","title":"Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2025-01-10","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":140},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT05895838","phase":"PHASE3","title":"The Danish Out-of-Hospital Cardiac Arrest Study","status":"RECRUITING","sponsor":"Christian Hassager","startDate":"2023-06-16","conditions":"Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome","enrollment":1000},{"nctId":"NCT03030417","phase":"PHASE1","title":"Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-27","conditions":"Solid Tumors, Lymphoma","enrollment":36},{"nctId":"NCT06288854","phase":"NA","title":"Efficacy of Olanzapine on Weight Gain in Advanced Gynecologic Cancer with Paclitaxel and Carboplatin: a Double Blind, Placebo-controlled Randomized Trial","status":"RECRUITING","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2024-04-03","conditions":"Weight Gain","enrollment":48},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT02939287","phase":"PHASE3","title":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2017-09-23","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT01029769","phase":"NA","title":"Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2009-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":350},{"nctId":"NCT06649214","phase":"PHASE3","title":"A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-11","conditions":"Schizophrenia","enrollment":654},{"nctId":"NCT05242874","phase":"PHASE3","title":"Anti-emetic Prophylaxis With or Without Dexamethasone","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2022-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":442},{"nctId":"NCT03201757","phase":"PHASE3","title":"Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2017-06-15","conditions":"Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder","enrollment":523},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT00212836","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04-21","conditions":"Schizophrenia","enrollment":481},{"nctId":"NCT06554613","phase":"PHASE2","title":"Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-12-01","conditions":"Non-Small Cell Lung Cancer","enrollment":156},{"nctId":"NCT00212784","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1225},{"nctId":"NCT06251635","phase":"NA","title":"Effects of Antipsychotics on Brain Insulin Action in Females","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-06-03","conditions":"Insulin Resistance, Menstrual Cycle, Type 2 Diabetes","enrollment":15},{"nctId":"NCT06500234","phase":"PHASE3","title":"Nutrition Impact on Immunotherapy of Cancer","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2024-06-01","conditions":"Nutrition Disorders, Immunotherapy, Cancer","enrollment":300},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT01617187","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-04","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT04524403","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-09-09","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":150},{"nctId":"NCT05213143","phase":"PHASE4","title":"The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine","status":"TERMINATED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2021-12-30","conditions":"Schizophrenia","enrollment":13},{"nctId":"NCT04833023","phase":"PHASE3","title":"HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial","status":"RECRUITING","sponsor":"Tan Tock Seng Hospital","startDate":"2022-05-18","conditions":"Haloperidol, Advanced Cancer, Hyperactive Delirium","enrollment":72},{"nctId":"NCT06338683","phase":"PHASE3","title":"Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","status":"RECRUITING","sponsor":"Qinghai Red Cross Hospital","startDate":"2024-03-20","conditions":"Advanced Cancer, Olanzapine, Progression Free Survival","enrollment":230},{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT06314906","phase":"PHASE3","title":"Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Feixue Song","startDate":"2024-03-07","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT00876772","phase":"PHASE2, PHASE3","title":"Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-03","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":40},{"nctId":"NCT05857566","phase":"PHASE1","title":"Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine","status":"COMPLETED","sponsor":"Response Pharmaceuticals","startDate":"2023-05-16","conditions":"Drug-induced Weight Gain","enrollment":24},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT04718727","phase":"PHASE1, PHASE2","title":"Olanzapine for the Prevention of Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Amani Hassan Abdel-Wahab","startDate":"2021-03-15","conditions":"Postoperative Nausea","enrollment":132},{"nctId":"NCT04750395","phase":"PHASE2","title":"Comparing Haloperidol and Olanzapine in Treating Terminal Delirium","status":"UNKNOWN","sponsor":"HCA Hospice Care","startDate":"2021-09-01","conditions":"Delirium, Terminal Illness","enrollment":80},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03187769","phase":"PHASE3","title":"Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2017-06-08","conditions":"Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder","enrollment":426},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT03246620","phase":"PHASE4","title":"Oral Olanzapine Versus Haloperidol or Diazepam","status":"TERMINATED","sponsor":"The University of Hong Kong","startDate":"2017-09-01","conditions":"Acute Agitation, Behavioural Emergency","enrollment":12},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05346731","phase":"PHASE3","title":"Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-04-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":210},{"nctId":"NCT00212771","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":440},{"nctId":"NCT00174265","phase":"PHASE3","title":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Schizophrenia","enrollment":196},{"nctId":"NCT00265343","phase":"PHASE3","title":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Schizophrenia","enrollment":306},{"nctId":"NCT00145496","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12","conditions":"Schizophrenia","enrollment":468},{"nctId":"NCT05202275","phase":"PHASE2","title":"The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-12-01","conditions":"Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma","enrollment":43},{"nctId":"NCT04232423","phase":"PHASE3","title":"Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-03-01","conditions":"Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis","enrollment":90},{"nctId":"NCT03066622","phase":"PHASE4","title":"Olanzapine for Acute Headaches","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2016-07","conditions":"Headache","enrollment":122},{"nctId":"NCT05123976","phase":"PHASE1","title":"Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.","status":"COMPLETED","sponsor":"Joint Stock Company \"Farmak\"","startDate":"2020-10-21","conditions":"Pharmacokinetics","enrollment":32},{"nctId":"NCT02161718","phase":"PHASE2","title":"A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2014-05","conditions":"Schizophrenia, Alcohol Use Disorder","enrollment":300},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03137121","phase":"PHASE2, PHASE3","title":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-07-12","conditions":"Advanced Cancer","enrollment":30},{"nctId":"NCT02873208","phase":"PHASE3","title":"A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-08-07","conditions":"Schizophrenia","enrollment":266},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT04536558","phase":"PHASE3","title":"Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-10-01","conditions":"Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy","enrollment":352},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT02755116","phase":"PHASE2","title":"Olanzapine for Nausea After Surgery","status":"COMPLETED","sponsor":"Jaime B Hyman","startDate":"2016-04","conditions":"Postoperative Nausea and Vomiting","enrollment":180},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT03877562","phase":"PHASE1","title":"The Effect of CORT118335 on Olanzapine-Induced Weight Gain","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-04-01","conditions":"Antipsychotic-induced Weight Gain","enrollment":96},{"nctId":"NCT02129478","phase":"PHASE2","title":"Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2014-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":15},{"nctId":"NCT03304457","phase":"PHASE4","title":"Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2017-08-25","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03230864","phase":"PHASE3","title":"Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2017-07-20","conditions":"Treatment-resistant Schizophrenia","enrollment":119},{"nctId":"NCT04181385","phase":"PHASE2, PHASE3","title":"Acute Olanzapine and Lipid Response","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-01-01","conditions":"Healthy","enrollment":15},{"nctId":"NCT02717195","phase":"PHASE3","title":"Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-04","conditions":"Schizophrenia","enrollment":1098},{"nctId":"NCT01687478","phase":"PHASE3","title":"A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2012-09","conditions":"Treatment Resistant Depression","enrollment":176},{"nctId":"NCT00324051","phase":"PHASE4","title":"Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-05","conditions":"Schizophrenia","enrollment":284},{"nctId":"NCT01625923","phase":"NA","title":"A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2013-01","conditions":"Idiopathic Gastroparesis","enrollment":3},{"nctId":"NCT03219710","phase":"PHASE3","title":"\"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)\"","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2017-07-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01567124","phase":"PHASE4","title":"Alleviating the Metabolic Side Effects of Antipsychotic Medications","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT03876938","phase":"PHASE3","title":"Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2019-03-01","conditions":"Antiemetic for Highly Emetogenic Chemotherapy","enrollment":147}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ATRIOVENTRICULAR BLOCK FIRST DEGREE"},{"count":1,"reaction":"BALANCE DISORDER"},{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"CLONIC CONVULSION"},{"count":1,"reaction":"COGWHEEL RIGIDITY"},{"count":1,"reaction":"CYANOSIS"},{"count":1,"reaction":"DIABETES MELLITUS"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"DRUG WITHDRAWAL SYNDROME"},{"count":1,"reaction":"EXTRAPYRAMIDAL DISORDER"}],"_approvalHistory":[],"publicationCount":206,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ZYPREXA®","ZYPREXA","LY170053","Zyprexa"],"phase":"marketed","status":"active","brandName":"Oral Olanzapine","genericName":"Oral Olanzapine","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Agitation associated with schizophrenia or bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}